NCT03762564View on ClinicalTrials.gov

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

July 4, 2022

Study Completion Date

November 25, 2022

Conditions

Squamous Cell Carcinoma of the Esophagus

Interventions

DRUG

Ramucirumab

Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 on day 1, 8, 15

Trial Locations (2)

60488

Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt

81675

Technische Universität München Klinikum rechts der Isar, München

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Trium Analysis Online GmbH

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT03762564 - Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy | Biotech Hunter | Biotech Hunter